Management of toxicities with novel systemic therapies in UC

Описание к видео Management of toxicities with novel systemic therapies in UC

Thomas Flaig, MD, University of Colorado Anschutz Medical Campus, Aurora, CO, provides an overview of the management of toxicities with novel systemic therapies in patients with urothelial carcinoma (UC), highlighting the use of antibody-drug conjugates in advanced disease. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.

Комментарии

Информация по комментариям в разработке